Utilization and impact of a rapid Candida panel on antifungal stewardship program within a large community hospital
Copyright © 2020 Elsevier Inc. All rights reserved..
BACKGROUND: The T2 Candida Panel (T2CP) bodes high sensitivity and specificity to detect candidemia, enabling providers to make quick therapy decisions and possibly decrease mortality. However, utilization in practice and clinical application remains to be evaluated.
OBJECTIVES: To evaluate the overall provider-utilization of the T2CP at a large community hospital.
METHODS: This single center, retrospective, observational study compared antifungal management in all patients with positive or negative T2CP. Additional endpoints included patient-specific variables influencing antifungal management decisions.
RESULTS: Six hundred twenty-eight T2CP results were evaluated. Antifungal optimization occurred in 54% of patients who had antifungal orders at the time of T2CP test. Antifungal therapy was avoided in 60.4% of negative cases. Patients with negative T2CP had significantly fewer days of therapy compared to positive tests.
CONCLUSIONS: Although the T2CP led to fewer days of antifungal therapy with negative tests, many opportunities for improvement in antifungal stewardship were identified, specifically, with negative tests.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
|---|---|
| Enthalten in: |
Diagnostic microbiology and infectious disease - 97(2020), 4 vom: 15. Aug., Seite 115086 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Steuber, Taylor D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal |
|---|
| Anmerkungen: |
Date Completed 05.04.2021 Date Revised 05.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diagmicrobio.2020.115086 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311145345 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311145345 | ||
| 003 | DE-627 | ||
| 005 | 20231225141630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diagmicrobio.2020.115086 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311145345 | ||
| 035 | |a (NLM)32535413 | ||
| 035 | |a (PII)S0732-8893(20)30463-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Steuber, Taylor D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utilization and impact of a rapid Candida panel on antifungal stewardship program within a large community hospital |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2021 | ||
| 500 | |a Date Revised 05.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The T2 Candida Panel (T2CP) bodes high sensitivity and specificity to detect candidemia, enabling providers to make quick therapy decisions and possibly decrease mortality. However, utilization in practice and clinical application remains to be evaluated | ||
| 520 | |a OBJECTIVES: To evaluate the overall provider-utilization of the T2CP at a large community hospital | ||
| 520 | |a METHODS: This single center, retrospective, observational study compared antifungal management in all patients with positive or negative T2CP. Additional endpoints included patient-specific variables influencing antifungal management decisions | ||
| 520 | |a RESULTS: Six hundred twenty-eight T2CP results were evaluated. Antifungal optimization occurred in 54% of patients who had antifungal orders at the time of T2CP test. Antifungal therapy was avoided in 60.4% of negative cases. Patients with negative T2CP had significantly fewer days of therapy compared to positive tests | ||
| 520 | |a CONCLUSIONS: Although the T2CP led to fewer days of antifungal therapy with negative tests, many opportunities for improvement in antifungal stewardship were identified, specifically, with negative tests | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antifungal | |
| 650 | 4 | |a Antimicrobial stewardship | |
| 650 | 4 | |a Candidemia | |
| 650 | 4 | |a Candidiasis | |
| 650 | 4 | |a Rapid diagnostics | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Tucker-Heard, Glady's |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Sawyer, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Thottacherry, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Hassoun, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostic microbiology and infectious disease |d 1986 |g 97(2020), 4 vom: 15. Aug., Seite 115086 |w (DE-627)NLM01262845X |x 1879-0070 |7 nnns |
| 773 | 1 | 8 | |g volume:97 |g year:2020 |g number:4 |g day:15 |g month:08 |g pages:115086 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diagmicrobio.2020.115086 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 97 |j 2020 |e 4 |b 15 |c 08 |h 115086 | ||